PHIBRO ANIMAL HEALTH CORP-A (PAHC) Stock Price, Forecast & Analysis

NASDAQ:PAHC • US71742Q1067

52.27 USD
-2.27 (-4.16%)
At close: Mar 3, 2026
52.27 USD
0 (0%)
After Hours: 3/3/2026, 8:00:02 PM

PAHC Key Statistics, Chart & Performance

Key Statistics
Market Cap2.12B
Revenue(TTM)1.46B
Net Income(TTM)92.09M
Shares40.53M
Float20.48M
52 Week High56.3
52 Week Low16.16
Yearly Dividend0.48
Dividend Yield0.88%
EPS(TTM)2.8
PE18.67
Fwd PE16.98
Earnings (Next)05-05
IPO2014-04-11
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
PAHC short term performance overview.The bars show the price performance of PAHC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

PAHC long term performance overview.The bars show the price performance of PAHC in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of PAHC is 52.27 USD. In the past month the price increased by 24.72%. In the past year, price increased by 121.11%.

PHIBRO ANIMAL HEALTH CORP-A / PAHC Daily stock chart

PAHC Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to PAHC. When comparing the yearly performance of all stocks, PAHC is one of the better performing stocks in the market, outperforming 95.14% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
PAHC Full Technical Analysis Report

PAHC Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to PAHC. PAHC has an excellent profitability rating, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PAHC Full Fundamental Analysis Report

PAHC Financial Highlights

Over the last trailing twelve months PAHC reported a non-GAAP Earnings per Share(EPS) of 2.8. The EPS increased by 73.91% compared to the year before.


Industry RankSector Rank
PM (TTM) 6.29%
ROA 6.55%
ROE 27.71%
Debt/Equity 2.14
Chartmill High Growth Momentum
EPS Q2Q%61.11%
Sales Q2Q%20.89%
EPS 1Y (TTM)73.91%
Revenue 1Y (TTM)32.39%
PAHC financials

PAHC Forecast & Estimates

9 analysts have analysed PAHC and the average price target is 46.24 USD. This implies a price decrease of -11.54% is expected in the next year compared to the current price of 52.27.

For the next year, analysts expect an EPS growth of 33.72% and a revenue growth 16.33% for PAHC


Analysts
Analysts48.89
Price Target46.24 (-11.54%)
EPS Next Y33.72%
Revenue Next Year16.33%
PAHC Analyst EstimatesPAHC Analyst Ratings

PAHC Ownership

Ownership
Inst Owners100.08%
Ins Owners0.52%
Short Float %5.23%
Short Ratio4
PAHC Ownership

PAHC Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO30.02962.369B
JNJ JOHNSON & JOHNSON21.18598.856B
MRK MERCK & CO. INC.22.15301.342B
PFE PFIZER INC8.85154.992B
BMY BRISTOL-MYERS SQUIBB CO10.06126.909B
ZTS ZOETIS INC18.3456.831B
RPRX ROYALTY PHARMA PLC- CL A9.1527.402B
VTRS VIATRIS INC5.9418.077B
ELAN ELANCO ANIMAL HEALTH INC23.6512.971B
AXSM AXSOME THERAPEUTICS INC N/A8.51B

About PAHC

Company Profile

PAHC logo image Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. The company is headquartered in Teaneck, New Jersey and currently employs 2,475 full-time employees. The company went IPO on 2014-04-11. The company develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. The company markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. The company has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

Company Info

PHIBRO ANIMAL HEALTH CORP-A

Glenpointe Centre East, 3Rd Floor, 300 Frank W. Burr Blvd., Suite 21

Teaneck NEW JERSEY 07666 US

CEO: Jack C. Bendheim

Employees: 2475

PAHC Company Website

PAHC Investor Relations

Phone: 12013297300

PHIBRO ANIMAL HEALTH CORP-A / PAHC FAQ

Can you describe the business of PHIBRO ANIMAL HEALTH CORP-A?

Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. The company is headquartered in Teaneck, New Jersey and currently employs 2,475 full-time employees. The company went IPO on 2014-04-11. The company develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. The company markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. The company has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.


What is the stock price of PHIBRO ANIMAL HEALTH CORP-A today?

The current stock price of PAHC is 52.27 USD. The price decreased by -4.16% in the last trading session.


What is the dividend status of PHIBRO ANIMAL HEALTH CORP-A?

PHIBRO ANIMAL HEALTH CORP-A (PAHC) has a dividend yield of 0.88%. The yearly dividend amount is currently 0.48.


How is the ChartMill rating for PHIBRO ANIMAL HEALTH CORP-A?

PAHC has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What sector and industry does PHIBRO ANIMAL HEALTH CORP-A belong to?

PHIBRO ANIMAL HEALTH CORP-A (PAHC) operates in the Health Care sector and the Pharmaceuticals industry.


Should I buy PAHC stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PAHC.


Can you provide the market cap for PHIBRO ANIMAL HEALTH CORP-A?

PHIBRO ANIMAL HEALTH CORP-A (PAHC) has a market capitalization of 2.12B USD. This makes PAHC a Mid Cap stock.